Pseudoresponse is a phenomenon initially identified during the trials featuring antiangiogenic therapies, like bevacizumab, which is designed to block the VEGF effect that is overexpressed in high-grade glioma tumors. The gene discussed is VEGFA; the disease is central nervous system cancer.